Regulatory T cells control diabetes without compromising acute anti-viral defense

Clinical Immunology

Volumn 153, Issue 2, 2014, Pages 298-307

  Baca Jones, Carmen ^a   Pagni, Philippe P ^a   Fousteri, Georgia ^a   Sachithanantham, Sowbarnika ^a   Dave, Amy ^a   Rodriguez Calvo, Teresa ^a   Miller, Jacqueline ^a   Von Herrath, Matthias ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Diabetes; ; Regulatory T cells; ; Safety; ; Stability; ; Therapy; Viral infection;

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; NEUROPILIN 1; PHENFORMIN; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEGENERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; GLUCOSE BLOOD LEVEL; HOST RESISTANCE; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; VIRAL CLEARANCE; VIRUS INFECTION; VIRUS LOAD; VIRUS TITRATION;

DIABETES;; REGULATORY T CELLS;; SAFETY;; STABILITY;; THERAPY; VIRAL INFECTION;;

ACUTE DISEASE; ADOPTIVE TRANSFER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GREEN FLUORESCENT PROTEINS; HOST-PATHOGEN INTERACTIONS; INTERFERON-GAMMA; INTERLEUKIN-10; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902661878     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.05.006     Document Type: Article

References (52)

1. Shevach E.M. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006, 25:195-201.
2. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004, 22:531-562.
3. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
4. Powrie F., Mason D. OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset. J. Exp. Med. 1990, 172:1701-1708.
5. Asano M., Toda M., Sakaguchi N., Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 1996, 184:387-396.
6. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155:1151-1164.
7. Eisenbarth G.S. Type I diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med. 1986, 314:1360-1368.
8. Filippi C.M., von Herrath M.G. Viral trigger for type 1 diabetes: pros and cons. Diabetes 2008, 57:2863-2871.
9. Bluestone J.A., Herold K., Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010, 464:1293-1300.
10. Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001, 358:221-229.
11. Maier L.M., Wicker L.S. Genetic susceptibility to type 1 diabetes. Curr. Opin. Immunol. 2005, 17:601-608.
12. Eaves I.A., Wicker L.S., Ghandour G., Lyons P.A., Peterson L.B., et al. Combining mouse congenic strains and microarray gene expression analyses to study a complex trait: the NOD model of type 1 diabetes. Genome Res. 2002, 12:232-243.
13. Coppieters K.T., Dotta F., Amirian N., Campbell P.D., Kay T.W., et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J. Exp. Med. 2012, 209:51-60.
14. Salomon B., Lenschow D.J., Rhee L., Ashourian N., Singh B., et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12:431-440.
15. Belghith M., Bluestone J.A., Barriot S., Megret J., Bach J.F., et al. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 2003, 9:1202-1208.
16. Gregori S., Giarratana N., Smiroldo S., Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J. Immunol. 2003, 171:4040-4047.
17. Wu A.J., Hua H., Munson S.H., McDevitt H.O. Tumor necrosis factor-alpha regulation of CD4+CD25+ T cell levels in NOD mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12287-12292.
18. Kukreja A., Cost G., Marker J., Zhang C., Sun Z., et al. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 2002, 109:131-140.
19. Jaeckel E., von Boehmer H., Manns M.P. Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes 2005, 54:306-310.
20. Lundsgaard D., Holm T.L., Hornum L., Markholst H. In vivo control of diabetogenic T-cells by regulatory CD4+CD25+ T-cells expressing Foxp3. Diabetes 2005, 54:1040-1047.
21. Tang Q., Henriksen K.J., Bi M., Finger E.B., Szot G., et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 2004, 199:1455-1465.
22. Herbelin A., Gombert J.M., Lepault F., Bach J.F., Chatenoud L. Mature mainstream TCR alpha beta+CD4+ thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse. J. Immunol. 1998, 161:2620-2628.
23. Lepault F., Gagnerault M.C. Characterization of peripheral regulatory CD4+ T cells that prevent diabetes onset in nonobese diabetic mice. J. Immunol. 2000, 164:240-247.
24. Marek-Trzonkowska N., Mysliwiec M., Dobyszuk A., Grabowska M., Techmanska I., et al. Administration of CD4+CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care 2012, 35:1817-1820.
25. Daifotis A.G., Koenig S., Chatenoud L., Herold K.C. Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin. Immunol. 2013, 149:268-278.
26. Herold K.C., Gitelman S.E., Ehlers M.R., Gottlieb P.A., Greenbaum C.J., et al. Teplizumab (anti-CD3 mAb) treatment preserves c-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013, 62:3766-3774.
27. Keymeulen B., Candon S., Fafi-Kremer S., Ziegler A., Leruez-Ville M., et al. Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood 2010, 115:1145-1155.
28. Luo X., Herold K.C., Miller S.D. Immunotherapy of type 1 diabetes: where are we and where should we be going?. Immunity 2010, 32:488-499.
29. Ohashi P.S., Oehen S., Buerki K., Pircher H., Ohashi C.T., et al. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991, 65:305-317.
30. Oldstone M.B., Nerenberg M., Southern P., Price J., Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991, 65:319-331.
31. Van Belle T.L., Taylor P., von Herrath M.G. Mouse models for type 1 diabetes. Drug Discov. Today Dis. Model. 2009, 6:41-45.
32. Holz A., Dyrberg T., Hagopian W., Homann D., von Herrath M., et al. Neither B lymphocytes nor antibodies directed against self antigens of the islets of Langerhans are required for development of virus-induced autoimmune diabetes. J. Immunol. 2000, 165:5945-5953.
33. Oxenius A., Bachmann M.F., Zinkernagel R.M., Hengartner H. Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection. Eur. J. Immunol. 1998, 28:390-400.
34. Fontenot J.D., Rasmussen J.P., Williams L.M., Dooley J.L., Farr A.G., et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005, 22:329-341.
35. Ejrnaes M., Filippi C.M., Martinic M.M., Ling E.M., Togher L.M., et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J. Exp. Med. 2006, 203:2461-2472.
36. Fantini M.C., Dominitzki S., Rizzo A., Neurath M.F., Becker C. In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells. Nat. Protoc. 2007, 2:1789-1794.
37. Levings M.K., Gregori S., Tresoldi E., Cazzaniga S., Bonini C., et al. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 2005, 105:1162-1169.
38. Unger W.W., Laban S., Kleijwegt F.S., van der Slik A.R., Roep B.O. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur. J. Immunol. 2009, 39:3147-3159.
39. Yamagiwa S., Gray J.D., Hashimoto S., Horwitz D.A. A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J. Immunol. 2001, 166:7282-7289.
40. Barrat F.J., Cua D.J., Boonstra A., Richards D.F., Crain C., et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 2002, 195:603-616.
41. Ye Z., Huang H., Hao S., Xu S., Yu H., et al. IL-10 has a distinct immunoregulatory effect on naive and active T cell subsets. J. Interferon Cytokine Res. 2007, 27:1031-1038.
42. Zhou X., Bailey-Bucktrout S.L., Jeker L.T., Penaranda C., Martinez-Llordella M., et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 2009, 10:1000-1007.
43. Duarte J.H., Zelenay S., Bergman M.L., Martins A.C., Demengeot J. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Eur. J. Immunol. 2009, 39:948-955.
44. Bailey-Bucktrout S.L., Martinez-Llordella M., Zhou X., Anthony B., Rosenthal W., et al. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 2013, 39:949-962.
45. Allan S.E., Crome S.Q., Crellin N.K., Passerini L., Steiner T.S., et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 2007, 19:345-354.
46. Miyao T., Floess S., Setoguchi R., Luche H., Fehling H.J., et al. Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity 2012, 36:262-275.
47. Rubtsov Y.P., Rasmussen J.P., Chi E.Y., Fontenot J., Castelli L., et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008, 28:546-558.
48. Liu X., Nguyen P., Liu W., Cheng C., Steeves M., et al. T cell receptor CDR3 sequence but not recognition characteristics distinguish autoreactive effector and Foxp3(+) regulatory T cells. Immunity 2009, 31:909-920.
49. Rubtsov Y.P., Niec R.E., Josefowicz S., Li L., Darce J., et al. Stability of the regulatory T cell lineage in vivo. Science 2010, 329:1667-1671.
50. Belkaid Y., Tarbell K. Regulatory T cells in the control of host-microorganism interactions (*). Annu. Rev. Immunol. 2009, 27:551-589.
51. Easterbrook J.D., Zink M.C., Klein S.L. Regulatory T cells enhance persistence of the zoonotic pathogen Seoul virus in its reservoir host. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15502-15507.
52. Oldenhove G., Bouladoux N., Wohlfert E.A., Hall J.A., Chou D., et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 2009, 31:772-786.